Single Treatment of Engineered Antibody Demonstrates 100 Percent Response Rate in Follicular Lymphoma
Monoclonal antibodies are small proteins directed against ³marker proteins,² known as antigens, present on the surface of tumor cells. This antibody, known as Anti-B1 Antibody, is directed against CD-20 antigens present on follicular lymphoma cancer cells. Radioactive iodine (I-131) attached to the monoclonal antibody provides directed killing of the cells to which it attaches.
The researchers of this study presented results from a phase II trial of I-131 Anti-B1 Antibody, conducted with patients not previously treated for follicular lymphoma. The results were quite impressive, with an initial tumor response rate of 100 percent -- 71% complete response and 9% partial response -- in 21 patients. Treatment was generally well-tolerated. This therapy appears to be a promising new agent for first-line treatment of follicular lymphoma, though larger trials will be needed to determine its long-term benefit.